AVNS: 15-12G · delisting
Avanos Medical, Inc. filed a Form 15 on August 6, 2026 to deregister its common shares, par value $0.01, under Section 12(g) of the Securities Exchange Act and to suspend its duty to file reports under Sections 13 and 15(d). The company relied on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) and reported approximately 1 holder of record, a level consistent with a recently completed going-private or acquisition transaction in which the public float was eliminated. As a result, Avanos will stop filing 10-K, 10-Q, and 8-K reports with the SEC, ending public financial transparency for the Alpharetta, Georgia-based medical products maker. The notice was signed by General Counsel and Secretary John S. Fischer.
AVNS: 8-K · acquisition merger
Avanos Medical, Inc. has completed its merger with A-AV Holdco I, Inc., an affiliate of American Industrial Partners, resulting in the company becoming a wholly-owned subsidiary of the parent entity. In connection with the closing, each share of Avanos common stock was cancelled and converted into the right to receive $25.00 in cash, without interest, representing a total aggregate merger consideration of approximately $1,200 million. The company notified the New York Stock Exchange that the merger was completed and requested the suspension of trading and delisting of its common stock. Trading was suspended on July 27, 2026, and the company intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act of 1934. To fund the transaction, the borrowers entered into a new credit agreement providing for an initial term loan facility of $675.0 million, a delayed draw term loan commitment of $100.0 million, and a revolving credit facility of $100.0 million. Additionally, the company's board of directors and officers were replaced as part of the change of control, with David C. Pacitti appointed as President and Chief Executive Officer.
American Industrial Partners Completes Acquisition of Avanos Medical, Inc.
American Industrial Partners completed its acquisition of Avanos Medical in a transaction valued at approximately $1.272 billion. Under the terms of the merger, stockholders received $25.00 per share in cash, and the company's common stock has ceased trading on the NYSE. CEO Dave Pacitti noted that AIP's operational depth will accelerate the innovation roadmap with greater resources.
Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners
Avanos Medical stockholders have voted to approve the acquisition of the company by affiliates of American Industrial Partners. Preliminary results indicate that 99.75% of shares voted were in favor of the transaction, representing approximately 75% of outstanding shares. Stockholders will receive $25.00 in cash per share upon the closing of the deal, which is expected no later than July 27, 2026.
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
S&P Dow Jones Indices announced that Avanos Medical will be removed from the S&P SmallCap 600 effective prior to the open on July 27. The deletion is driven by the pending acquisition of Avanos by American Industrial Partners, a deal expected to close soon.
AVNS: 8-K · proxy statement
Avanos Medical, Inc. filed a Form 8-K to supplement its definitive proxy statement regarding its pending acquisition by affiliates of AIP, responding to lawsuits and demand letters that alleged disclosure deficiencies. The company stated it is voluntarily providing the additional information to avoid delaying the merger, scheduled for a shareholder vote on July 22, 2026, while denying any liability or wrongdoing. The supplemental disclosure details financial advisor J.P. Morgan’s analysis, listing comparable companies such as Align Technology and ICU Medical with forward multiples ranging from 7.0x to 12.6x. This analysis implied an equity value range of $12.75 to $23.50 per share, which falls below the Merger Consideration of $25.00 per share. Additional disclosures included a breakdown of management’s Adjusted EBITDA forecast of $82.4 million for the twelve months ending March 31, 2026, and a confirmation that UBS estimates receiving a fee of not more than $5 million. Avanos’ board continues to recommend that stockholders vote in favor of the merger proposals.
Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
Avanos Medical and American Industrial Partners have received all required regulatory approvals for the pending acquisition of Avanos by affiliates of AIP. The transaction is expected to close no later than July 27, 2026, subject to stockholder approval at a special meeting scheduled for July 22, 2026. Management characterized the regulatory clearance as a significant milestone that brings the company closer to completing the transaction and embarking on its next phase of growth.
Are CRBG, EQH, AVNS Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating the proposed sale of Avanos Medical to affiliates of American Industrial Partners for $25.00 per share in cash. The firm is examining whether the transaction constitutes a fair deal for shareholders or if terms limit superior competing offers. Shareholders are being solicited to contact the law firm on a contingency fee basis to discuss their rights.
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC issued a shareholder-solicitation notice naming AVNS, NUVL, XOMA, and TBRG; no new disclosure from the companies themselves. The release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis. This is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.
AVNS: DEFM14A · acquisition merger
Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by A-AV Holdco I, Inc., a special purpose vehicle affiliated with private equity firm American Industrial Partners. The Board of Directors unanimously recommends the merger, which will result in Avanos being taken private and delisted from the NYSE. Stockholders will receive $25.00 per share in cash, representing a significant premium to the $14.53 closing price on the day prior to the announcement. The transaction is valued at approximately $1.42 billion, funded by $1.4 billion in equity from American Industrial Partners Capital Fund VIII and additional debt financing. A special meeting of stockholders is scheduled for July 22, 2026, to vote on the merger proposal. The deal is subject to customary closing conditions, including stockholder approval, regulatory clearances, and the absence of a superior proposal. J.P. Morgan has provided a fairness opinion supporting the transaction.
Are CZR, AVNS, GBTG Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC issued a shareholder-solicitation notice naming Avanos Medical (AVNS), Caesars Entertainment (CZR), and Global Business Travel Group (GBTG); no new disclosure from the companies themselves. The release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis regarding the proposed M&A transactions. This is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.
AVNS: PREM14A · acquisition merger
Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by A-AV Holdco I, Inc., a special purpose vehicle affiliated with private equity firm American Industrial Partners. The merger will result in Avanos being taken private, with all outstanding shares converted into the right to receive $25.00 per share in cash. The deal values the company at approximately $1.42 billion, representing a significant premium of roughly 72% over Avanos' closing stock price of $14.53 on April 13, 2026, the last trading day before the announcement. J.P. Morgan Securities LLC has rendered a fairness opinion stating that the merger consideration is fair, from a financial point of view, to Avanos stockholders. Stockholders are being asked to vote on the merger proposal at a special meeting, with the Board of Directors unanimously recommending approval. The transaction is expected to close in the second half of 2026, subject to stockholder approval, regulatory clearances, and other customary closing conditions. Upon completion, Avanos' common stock will be delisted from the NYSE and deregistered under the Exchange Act.
Avanos Medical, Inc. Announces First Quarter 2026 Results
Avanos Medical reported Q1 2026 net sales of $182.2 million, an 8.8% increase year-over-year, though net income fell to $5.1 million from $6.6 million in the prior year. The company announced it has signed a definitive agreement to be acquired by affiliates of American Industrial Partners in an all-cash transaction valued at $1.272 billion. Specialty Nutrition Systems drove growth with sales of $124.0 million, while the Pain Management & Recovery segment remained flat at $56.3 million.
